EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The landscape of nanoparticle-based siRNA delivery and therapeutic development

Muhammad Moazzam, Mengjie Zhang, Abid Hussain, Xiaotong Yu, Jia Huang, Yuanyu Huang

Molecular Therapy · 2024-02 · 32 (2) · 284-312

DOI: 10.1016/j.ymthe.2024.01.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2024-02. Verfasst von Muhammad Moazzam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Engineering and Science, University of Greenwich, Medway Campus, Chatham Maritime, Kent ME4 4TB, UK. Hauptthemen laut MEDLINE: Polymers, Nanoparticles, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 245-mal zitiert (Crossref) und nennt 287 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Nova Program, Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Five small interfering RNA (siRNA)-based therapeutics have been approved by the Food and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and vutrisiran. Besides, siRNA delivery to the target site without toxicity is a big challenge for researchers, and naked-siRNA delivery possesses several challenges, including membrane impermeability, enzymatic degradation, mononuclear phagocyte system (MPS) entrapment, fast renal excretion, endosomal escape, and off-target effects. The siRNA therapeutics can silence any disease-specific gene, but their intracellular and extracellular barriers limit their clinical applications. For this purpose, several modifications have been employed to siRNA for better transfection efficiency. Still, there is a quest for better delivery systems for siRNA delivery to the target site. In recent years, nanoparticles have shown promising results in siRNA delivery with minimum toxicity and off-target effects. Patisiran is a lipid nanoparticle (LNP)-based siRNA formulation for treating hereditary transthyretin-mediated amyloidosis that ultimately warrants the use of nanoparticles from different classes, especially lipid-based nanoparticles. These nanoparticles may belong to different categories, including lipid-based, polymer-based, and inorganic nanoparticles. This review briefly discusses the lipid, polymer, and inorganic nanoparticles and their sub-types for siRNA delivery. Finally, several clinical trials related to siRNA therapeutics are addressed, followed by the future prospects and conclusions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PolymersNanoparticlesAmyloid Neuropathies, FamilialRNA, Small InterferingTransfectionLipids

Stichwörter der Autor:innen

RNA interferenceclinical trialsinorganic carrierlipid nanoparticlepolymersiRNA

Substanzen

RNA, Small InterferingPolymersLipids

Autor:innen und Institutionen

  • Faculty of Engineering and Science, University of Greenwich, Medway Campus, Chatham Maritime, Kent ME4 4TB, UK.
  • School of Life Science, Advanced Research Institute of Multidisciplinary Science, School of Medical Technology, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmac…
  • Department of Immunology, School of Basic Medical Sciences, Key Laboratory of Medical Immunology of Ministry of Health, Peking University, Beijing 100191, China. Electronic address: xiaotong_pharm@pku.edu.cn.
  • Department of Hepatobiliary Surgery, China-Japan Friendship Hospital, Beijing 100029, China. Electronic address: huangjia@zryhyy.com.cn.

Förderung

  • Beijing Nova Program
  • Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
  • National Key Research and Development Program of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Moazzam, M., Zhang, M., Hussain, A., Yu, X., Huang, J., & Huang, Y. (2024). The landscape of nanoparticle-based siRNA delivery and therapeutic development. Molecular Therapy, 32(2), 284-312. https://doi.org/10.1016/j.ymthe.2024.01.005

Vancouver

Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y. The landscape of nanoparticle-based siRNA delivery and therapeutic development. Molecular Therapy. 2024;32(2):284-312. doi:10.1016/j.ymthe.2024.01.005

BibTeX
@article{Moazzam2024,
  author = {Moazzam, Muhammad and Zhang, Mengjie and Hussain, Abid and Yu, Xiaotong and Huang, Jia and Huang, Yuanyu},
  title = {The landscape of nanoparticle-based siRNA delivery and therapeutic development},
  journal = {Molecular Therapy},
  year = {2024},
  volume = {32},
  number = {2},
  pages = {284--312},
  doi = {10.1016/j.ymthe.2024.01.005}
}
Kostenlos starten →